170 filings
Page 2 of 9
8-K
ka2hyrfnq8c hrbmxl
12 Apr 22
Other Events
4:07pm
8-K
l9ehn220
12 Apr 22
Regulation FD Disclosure
9:00am
8-K
9euf6w
28 Feb 22
Humanigen Reports Year-End 2021 Financial Results
4:01pm
8-K
oj3fkz4 f3qrte8
5 Jan 22
Other Events
6:04am
8-K
msf2z vh4vqka
2 Dec 21
Other Events
8:00am
8-K
6enlnanbn2o35zs
26 Nov 21
Departure of Directors or Certain Officers
5:00pm
8-K
57ge1v 6a7kg
12 Nov 21
Results of Operations and Financial Condition
4:01pm
8-K
7ux3laevonw1h
9 Nov 21
Regulation FD Disclosure
8:00am
8-K
ezkg2ntyo8
20 Oct 21
Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors
9:13am
8-K
ztuln1y0
5 Oct 21
Departure of Directors or Certain Officers
4:05pm
8-K
paqgsi2y 2fgk8jm
14 Sep 21
Regulation FD Disclosure
5:00pm
8-K
izams8jhb wmn2ra0aff
10 Sep 21
Other Events
6:01am
8-K
91z4ub
12 Aug 21
Humanigen Reports Second Quarter 2021 Financial Results
4:01pm
8-K
d6bttbx
4 Aug 21
Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
6:04am
8-K
jh2wq9psd77c4rv64b
14 Jul 21
Regulation FD Disclosure
11:58am
8-K
p3k27p5atekkxbeh
21 Jun 21
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
aotxik2
17 Jun 21
Humanigen 2021 Annual Stockholder Meeting June 17
6:30am
8-K
27to73qklvhzrtwlsdor
28 May 21
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
5:00pm
8-K
aaya9 80p0b2
13 May 21
Humanigen Reports First Quarter 2021 Financial Results
4:06pm
8-K
c2nct
20 Apr 21
Humanigen Reports Positive Data with Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
5:28pm